MedTrace Logo

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00633880 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2014-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Conditions

  • Symptomatic Neurogenic Orthostatic Hypotension (NOH)
  • Non-diabetic Neuropathy
  • Primary Autonomic Failure
  • Dopamine Beta Hydroxylase Deficiency

Interventions

DRUG

Placebo

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

DRUG

Droxidopa

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY

  • Chelsea Therapeutics

    lead INDUSTRY

Principal Investigators

  • Horacio Kaufmann, MD · NYU Langone Health

  • Christopher J Mathias, MD · Imperial School of Medicine

  • Roy Freeman, MD · Harvard Medicine School

  • Phillip A Low, MD · Mayo Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States
  • Australia
  • Canada
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633880 on ClinicalTrials.gov